CN108578510A - A kind of drug for treating slow arrhythmia - Google Patents
A kind of drug for treating slow arrhythmia Download PDFInfo
- Publication number
- CN108578510A CN108578510A CN201810852307.2A CN201810852307A CN108578510A CN 108578510 A CN108578510 A CN 108578510A CN 201810852307 A CN201810852307 A CN 201810852307A CN 108578510 A CN108578510 A CN 108578510A
- Authority
- CN
- China
- Prior art keywords
- drug
- heart
- group
- treatment
- slow arrhythmia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 119
- 229940079593 drug Drugs 0.000 title claims abstract description 77
- 206010003119 arrhythmia Diseases 0.000 title claims abstract description 68
- 230000006793 arrhythmia Effects 0.000 title claims abstract description 68
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 22
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 22
- 241000522254 Cassia Species 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 12
- 241001165494 Rhodiola Species 0.000 claims abstract description 12
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 12
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 12
- 239000003826 tablet Substances 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000004615 ingredient Substances 0.000 claims abstract description 6
- 238000007796 conventional method Methods 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 59
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 description 85
- 208000011580 syndromic disease Diseases 0.000 description 58
- 239000006187 pill Substances 0.000 description 46
- 230000007812 deficiency Effects 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 208000024891 symptom Diseases 0.000 description 31
- 230000002861 ventricular Effects 0.000 description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 208000000059 Dyspnea Diseases 0.000 description 11
- 206010013975 Dyspnoeas Diseases 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000013220 shortness of breath Diseases 0.000 description 8
- 206010042772 syncope Diseases 0.000 description 8
- 239000011800 void material Substances 0.000 description 8
- 206010063659 Aversion Diseases 0.000 description 7
- 206010029216 Nervousness Diseases 0.000 description 7
- 230000036471 bradycardia Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 206010029410 night sweats Diseases 0.000 description 6
- 230000036565 night sweats Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 206010040639 Sick sinus syndrome Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010040007 Sense of oppression Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 208000006218 bradycardia Diseases 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000009524 danshen dripping Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- 241000227129 Aconitum Species 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000269420 Bufonidae Species 0.000 description 2
- 241000208296 Datura Species 0.000 description 2
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- OEYQBKYISMRWQB-UHFFFAOYSA-N Santal Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 OEYQBKYISMRWQB-UHFFFAOYSA-N 0.000 description 2
- 206010047284 Ventricular asystole Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 210000003056 antler Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 2
- 238000013546 non-drug therapy Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007674 radiofrequency ablation Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 206010063429 Aase syndrome Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000008659 shensongyangxin Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 239000005538 withdrawn drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of drug for treating slow arrhythmia, which is made of effective ingredient and medically acceptable excipient, wherein the effective ingredient is made of the bulk pharmaceutical chemicals of following weight percent：Herba Epimedii 23~28%, Chinese cassia tree 9~11%, Radix Astragali 18~22%, Schisandra chinensis 14~17%, rhodiola root 9~11%, Radix Notoginseng 9~11%, dried orange peel 9~11%.Common granule, capsule or tablet can be made in drug of the present invention according to a conventional method.According to clinical verification, treatment slow arrhythmia of the present invention curative effect of medication is notable and without any adverse reactions and toxic side effect.
Description
Technical field
The present invention relates to medicinal preparations, and in particular to contains the treatment Retarder theory rhythm of the heart mistake for not determining structure from plant
Normal Chinese medicine preparation
Background technology
Slow arrhythmia is clinical common arrhythmia cordis.Arrhythmia cordis can by coronary heart disease, hypertensive cardiopathy,
Heart failure, a variety of diseases such as vital myocarditis, hypothyroidism, vegetative nerve functional disturbance cause.It is clinically
Activity palpitation is not peaceful in the minds of often showing as, and feels and beats in the heart, is panic-stricken, cannot be autonomous, in paroxysmal or lasts more than, with chest
Bored, shortness of breath and fatigue, even ambition pain, syndrome characterized by dyspnea limb cold sweat goes out, syncope.Belong to Chinese medicine " palpitaition " scope.With rhythm of life is fast,
Operating pressure is big, psychological stress is strong, such as adds that habits of smoking and alcohol drinking are more, factor is lacked in physical exertion, leads to arrhythmia cordis gradually year
Lightization, the incidence of the arrhythmia cordis such as slow arrhythmia are in dramatically increase trend.It is put into practice from Present clinical, the Retarder theory heart
It restrains that not normal pathogenesis is mostly in the majority with the deficiency of yang, deficiency of vital energy person, often shows as based on void, the heart kidney yang gas of simulataneous insufficiency and excessive loses
Empty, the stagnant obstructed syndrome of the heart arteries and veins stasis of blood, disease feature can be summarized as void, the stasis of blood, phlegm.Therefore it is living to be placed on QI invigorating temperature sun more for the emphasis for the treatment of
In terms of blood.
The common palpitaition of clinical manifestation, weak, dizzy, uncomfortable in chest, angina pectoris, the expiratory dyspnea of slow arrhythmia are even dizzy
It faints.Currently, including drug and non-drug therapy for the total therapeutic strategy of slow arrhythmia.The main needle of non-drug therapy
Arrhythmia cordis that is invalid to drug therapy, breaking out frequently or serious haemodynamics adverse consequences can be caused, such as RF ablation, peace
Pacemaker etc. is filled, it is costly, and there is stringent indication and contraindication, to most of slow arrhythmia patients
And be not suitable for, it is exactly that RF ablation is postoperative to cause bradycardia because having done to have many patients.Therefore in the period of considerably long in
Drug therapy is still the treatment main line of slow arrhythmia.But the anti-slow arrhythmia of several classes of current Clinical practice
There is common deficiencies for drug, first, curative effect is not good enough, second is that inducing the hair of new arrhythmia cordis when treatment arrhythmia cordis again
It is raw.
Europe and the U.S. consume more than 600 hundred million dollars of traditional herbal medicines every year at present, and the world is more elsewhere, especially exists
Far Eastern country.Therefore, antiarrhythmic Chinese medicine is studied, not only there are extensive market prospects at home, it is interior at the international level
With the very big market space.But since form of Chinese drug is not fixed, pharmacological research is not illustrated deeply, takes not convenient equal limit
The performance of its advantage is made.The anti-slow arrhythmia Chinese patent drug that further research and development curative effect is stablized, will become future
The therapeutic new hot spot of one period cardiovascular drugs.
Still lack the good effect drug for the treatment of slow arrhythmia at present, in contrast, Chinese medicine effect is generally preferred over Western medicine,
And it is small with toxic side effect, it is suitble to take for a long time, advantage at low cost.The Chinese medicine of the disease is treated at present mostly with QI invigorating Warming Yang and promoting blood circulation
Based on drug, as Chinese ephedra, asarum, monkshood, Radix Codonopsis, sealwort, Radix Salviae Miltiorrhizae, datura flower, ginseng, Chinese cassia tree, pilose antler, borneol, muscone,
Radix Notoginseng, safflower, rhizoma nardostachyos, Radix Ophiopogonis, cassia twig, santal, the dried venom of toads, jujube etc., and to have effects that the drug of QI invigorating Warming Yang and promoting blood circulation is
The compound and its preparation of main composition, such as heart treasure pill, Shen Song Yang Xin Capsule etc..Since said medicine is with the dry strong drug of temperature compensation
It is main, for quite a few and folder yin deficiency syndrome person, easy to produce malaise symptoms.Therefore, pools of traditional Chinese medicine is excavated, is innovated and perfect
Slow arrhythmia therapy theory, finds the treatment more efficiently Chinese medicine preparation of slow arrhythmia, not only has higher
Learning value, and wide market can obtain good social and economic effects.
Invention content
The purpose of the present invention is to provide a kind of drug of new treatment slow arrhythmia, which can effectively change
Kind symptom, treatment slow arrhythmia are significant in efficacy.
The present invention realizes that the technical solution of above-mentioned purpose is：
A kind of drug for treating slow arrhythmia, the drug is by effective ingredient and medically acceptable excipient group
At wherein the effective ingredient is made of the bulk pharmaceutical chemicals of following weight percent：
Herba Epimedii 23~28%, Chinese cassia tree 9~11%, Radix Astragali 18~22%, Schisandra chinensis 14~17%, rhodiola root 9~11%,
Radix Notoginseng 9~11%, dried orange peel 9~11%.
Drug of the present invention, wherein the optimum proportioning of the bulk pharmaceutical chemicals is：
Herba Epimedii 25%, Chinese cassia tree 10%, Radix Astragali 20%, Schisandra chinensis 15%, rhodiola root 10%, Radix Notoginseng 10%, dried orange peel 10%.
The drug for the treatment of slow arrhythmia of the present invention, is made by following methods：
(1) Radix Notoginseng is taken, it is the circumfluence distillation 3 times of 70% ethyl alcohol to add 8 times of amount volumetric concentrations, 1.5 hours every time, collects and closes
And alcohol extract, filtration, decompression filtrate recycling ethanol is simultaneously concentrated into medicinal extract, spare；
(2) it takes remaining bulk pharmaceutical chemicals to add water to cook 3 times, is fried by intense fire after boiling for the first time 30 minutes, force after boiling for the second time
Fire is decocted 1 hour, is fried by intense fire after boiling for the third time 1.5 hours, collecting decoction, is filtered, filtrate decompression is concentrated into medicinal extract, spare；
(3) medicinal extract obtained by step (1) and (2) is collectively disposed in baking oven, dry cream is baked at 75 DEG C, be ground into thin
Powder；
(4) it takes the fine powder obtained by step (3) that suitable acceptable excipient of medicine is added, is made according to a conventional method often
Solid oral agent.
Above-mentioned common solid oral agent, be according to a conventional method made of granule, capsule or tablet.
Drug of the present invention is equipped with Radix Astragali, Schisandra chinensis, rhodiola root, Radix Notoginseng, dried orange peel using Herba Epimedii, Chinese cassia tree as main ingredient
It is made.Wherein, Herba Epimedii, Chinese cassia tree temperature compensation heart kidney, rouse oneself yang-energy be monarch drug in a prescription；It is aided with Radix Astragali, Schisandra chinensis benefiting qi and nourishing yin nourishing heart is reinforced
Monarch drug in a prescription QI invigorating calming heart, then with rhodiola root, monarch drug in a prescription is promoting blood circulation and removing blood stasis promotes blood circulation for Radix Notoginseng auxiliary, the two is combined into ministerial drug；With dried orange peel qi-regulating
Phlegm, coordinating the drug actions of a prescription are to make medicine.Full side's temperature compensation heart kidney, supplementing qi and nourishing yin, blood circulation and channel invigorating, stagnation resolvation is without hindering just, and temperature compensation is without impairment of yin.
Drug of the present invention can effectively treat nervous palpitaition caused by slow arrhythmia, syncope, shortness of breath, tired, chest
The symptoms such as bored pectoralgia, and the objective indicators such as average ventricular rate, average heart rate, most slow heart rate and most fast heart rate that can improve patient,
And without apparent toxic side effect.
Drug therapy of the present invention is slow to be shown up to the clinical study results more than 3 years to 246 slow arrhythmia patients
Chronic arrhythmia cordis tool has a better effect, and reaches 85.19% according to the electrocardiogram ventricular rate efficacy evaluation total effective rate that is averaged, presses
Reach 93.83% according to Chinese medicine syndrome integral efficacy evaluation total effective rate.Invention drug to the therapeutic effect of slow arrhythmia,
Can be observed by following clinical cases is further confirmed.
The relevant criterion of 1 clinical experimental study
1.1 diagnostic criteria
(1) Western medicine diagnostic criteria：Sick sinus syndrome, atrioventricular block, brady-tachy arrhythmia syndrome diagnosis, with reference to the U.S.
Cardiology can defined I class pacemaker indication；(2) tcm diagnosis standard：According to《New Chinese medicine guideline of clinical investigations
Standard (second volume)》It is formulated about palpitaition, sick sinus syndrome related guidance principle.
1.2 inclusion criteria
(1) voluntary participation, informed consent；(2) meet Western medicine diagnostic criteria, while meeting the following conditions：24 hours total hearts
Number of fighting is less than 80000 times, but more than 70000 times；There is ventricular asystole ＜ 3s or patients with atrial fibrillation ventricular asystole in sinus rhythm patient
＜ 5s；I Aminophyline of atrioventricular conduction time ＜ 300ms；(3) meet tcm diagnosis standard；(4) age 18~85
Year；(5) it does not take or has withdrawn drug influential on arrhythmia cordis 2 weeks, include negative chronotropic, negativity conduction and the influence heart
The drug of flesh energetic supersession.
1.3 exclusion criteria
(1) age is less than 18 years old or is more than 85 years old；(2) controlling of blood pressure is bad, i.e. and systolic pressure >=160mmHg or diastolic pressure >=
100mmHg；(3) diabetes do not control, fasting blood-glucose >=7.0mmol/L, postprandial 2 hours blood glucose >=11.0mmol/L, and be saccharified blood
Hemoglobin concentration >=7.5%；(4) there are serious hepatic and kidney function obstacle persons such as with active hepatitis, alcoholic liver whole latter stage, liver cancer
The diseases patient such as late period, uremia；There is the laboratory examination abnormal index of clinical meaning：Liver transaminases, alkaline phosphatase before selected
The indexs such as enzyme, bilirubin are higher than 3 times of normal upper limit, and plasma albumin is less than 30g/L, and serum creatinine is higher than normal value, and blood potassium is less than
3.5mmol/L is higher than 5.5mmol/L；(5) other systems disease is suffered from, in fact it could happen that serious to damage or have mental act abnormal
Person, if cirrhotic patients with portal hypertension is likely to occur massive hemorrhage of gastrointestinal tract, hepatic encephalopathy, the Systemic Lupus Activity phase may go out
Existing heart, kidney or nervous system damage；(6) it currently indulges in excessive drinking or takes drugs, or screening in first 5 years has alcohol or drug indiscriminate
Use history；(7) gestation or women breast-feeding their children, Women of Childbearing Age (do not take sterilization measure or non-menopausal women, impasse to be defined as stopping
It is more than 1 year through the time) the preceding urine HCG negative findings that obtain must be selected in exclude gestation；(8) other are participated in (in 2 months) in the recent period to face
Bed development test but the person of dropping by the wayside withdraw other Chinese medicines not up to 2 weeks persons；(9) there is serious cardiovascular and cerebrovascular disease within nearly 6 months
And damage non-recuperator；(10) secondary slow arrhythmia caused by the other reasons such as drug or electrolyte disturbance；
(11) pacemaker person；(12) height or third degree A-V block or other severe arrhythmias induce aase's syndrome
Person；(13) medication cannot be adhered to as required or refuses signature informed consent form person.
1.4 subjects' falls off
(1) case that falls off judges：Filled in subject's informed consent form and by screening enrolled patient, no matter because
For when which kind of reason (voluntarily exiting, compliance is poor, lost to follow-up etc.), as long as the subject that the defined observation period does not complete,
It is the case that falls off.If the case to fall off there are data after the treatment of baseline, index the effect of last time can be carried over to
It is final as a result, for statistical analysis；(2) processing for the case that falls off：For the subject to fall off, phone, electronics can be taken
The modes such as mail, visit to the parents of schoolchildren or young workers contact subject.Inquire reason, the as far as possible index of the assessment in completion scheme.Fall off the disease of patient
The data of the CRF tables of people will put on record preservation, so as to FAS set analysis after the test.
1.5 subjects reject
(1) standard be included in and excluded for entering group and having violated scheme of case, should not be random enrolled；(2) subject is not
Obey enter at random group or it is random after do not take medicine or drug administration (10% total experiment dosage)；(3) midway
The other Chinese patent drugs to affect the treatment with safety evaluatio are used；(4) after entering group at random, not any treatment data.
1.6 testing the standard stopped
(1) serious safety problem has occurred in test, it should stop experiment immediately；(2) medicine is found during experiment
Object does not have clinical value, is effectively treated in order to avoid delaying subject, it should stop experiment；(3) researcher test into
Find that scheme has significant error or severe deviations have occurred in scheme implementation process during exhibition；(4) sponsor tested
Because the reasons such as funds, management stop experiment；(5) National Drug Administration orders because of cause specific and stops to test.
2 clinical datas and research method
2.1 research method
(1) research and design：This experiment uses randomized controlled trial.(2) method of randomization：It is random using district's groups, parallel right
According to method table of random number is generated according to the case load of distribution and ratio by SAS softwares.(3) it is included in case source：
All subjects, which come from, to go to a doctor in Guangzhou Hospital of Southern Medical University, Guang Zhounan in December, 2016 in January, 2013-
The square hospitals of traditional Chinese and western medicine of medical university simultaneously meet the (reference of slow arrhythmia diagnostic criteria《Modern heart clinical practice》With
《Clinical electrocardiography》The diagnostic criteria of bradycardia arrhythmia cordis,《New Chinese medicine guideline of clinical investigations standard》System
Outpatient service calmly), inpatient.
2.2 therapeutic scheme
Clinical test according to《Declaration of Helsinki》Principle and drug clinical trial quality management practices
(Goodclinicalpractice, GCP) requires to carry out.Tranquil heart rate is counted daily 1 time；It has an electro-cardiogram weekly 1 time；Observation is complete
Dynamic electrocardiogram after portion patient treats 8 weeks and before treatment Fig. 1 times, compares pretherapy and post-treatment curative effect.
(1) trial drug：
1. treatment group：Treat the granule that medication is following embodiments 1, each 15g, warm boiled water.3 times a day, even
Continuous medication 8 weeks.
2. heart treasure pill group：Using the heart treasure pill (Chinese medicines quasi-word Z44O21843) produced by Guangdong Xin Bao drugmakers, every
60mg.Give heart treasure pill 5 (300mg) every time, 3 times a day, warm water is taken after mixing it with water, and is continuously taken 8 weeks.
3. complex group：Using conventional compound medication, Radix Notoginseng total glucosides tablet (Daphne Pharmaceutical (Group) Co., Ltd.Yunnan) is given
Each 100mg, 10 tablets each time, (Community in Baiyunshan, Guangzhou Pharmaceutical Group share is limited for Inosine tablets for compound danshen dripping pills (Tianjin day scholar's power)
Company's White Cloud Mountain pharmacy head factory) 0.2 gram every time, three times a day, warm water delivery service.
Spicy food is avoided during medication, avoids spirits.It is as a treatment course with 8 weeks.It participates in withdrawing it from clinical test the last week
Its antiarrhymic.It is discontinued and checks in latter week.
(2) drug combination provides：The Chinese medicine and Chinese patent drug of other treatment arrhythmia cordis are forbidden to use during experiment, or to controlling
Treat the influential Chinese medicine of arrhythmia cordis curative effect and Chinese patent drug.It is constant with the treatment of other diseases.For complication such as diabetes,
Hypertension, dyslipidemia, heart failure, hypotensive shock etc. should give anti symptom treatment according to associated guideline.All drug combinations are all
Must be recorded in detail in original record (patient medical history/inpatient cases) and CRF, including medicine title, per total daily dose,
Slurry pump, is discontinued the date at medication Start Date.
2.3 observation index
(1) Population demographic indicators associated：Gender, age, date of birth, nationality, height, weight.Remember before importing database
Record information above.
(2) general clinical data：Present illness history (including the course of disease, medicining condition etc.), medical history, medication history, allergies, suction
Cigarette and situation etc. of drinking.Information above is recorded before importing database.
(3) endpoint (curative effect index)：Average ventricular rate efficacy evaluation：With reference to the national combination of Chinese tradiational and Western medicine in 1979
Prevention and treatment of coronary heart disease, angina pectoris, arrhythmia cordis research forum《The common arrhythmia cordis cause of disease, severity and curative effect reference standard》
It formulates.It is effective：Clinical symptoms are obviously improved or disappear substantially, and heart rate increases by 10 beats/min of ＞ or more；Effectively：Clinical symptom relief,
Heart rate increases to be mitigated up to 5 beats/min or more or electrocardio diagram conductive impairment；In vain：Clinical symptoms increase without improvement, heart rate less than 5
Beat/min, electrocardiogram is identical before relatively treating or conductive impairment aggravates.
(4) secondary efficacy index：Tcm syndrome curative effect：It is indicated using tcm syndrome element integration method.1. clinical recovery：It is former
There are symptom, sign to disappear substantially, total mark reduces >=90%；2. effective：Original symptom, sign largely disappear or obviously subtract
Gently, total mark reduces >=70%, ＜ 90%；3. effectively：Original symptom, sign mitigate before relatively treating, and total mark reduces >=30%,
＜ 70%；4. invalid：Without improvement, total mark reduces ＜ 30% for original symptom, sign.
(5) safety detection：1. vital sign：Including：(heart rate, body temperature, breathing, blood pressure), needs under rest state
It measures, blood pressure measurement uniformly takes seat blood pressure.Baseline 0 day, medication ± 7 days the 8th week, be discontinued after ± 7 days the 4th week.2. physique is examined
It looks into：Only record positive sign.Especially whether there is or not the performances such as blutpunkte, ecchymosis for record body surface.Baseline 0 day, medication ± 7 days the 12nd week,
± 7 days the 4th week after drug withdrawal.3. laboratory examination：Blood routine, routine urinalysis, just routine；Glutamic-pyruvic transaminase, glutamic-oxalacetic transaminease；Blood urine
Plain nitrogen, blood uric acid, serum creatinine, glomerular filtration rate；Coagulation function；Troponin；Blood fat situation；Hs-CRP feelings
Condition.4. Adverse event monitoring：Overall process monitoring is tested, is recorded in detail at any time
2.4 statistical analysis
Test data uses SAS9.3 statistical softwares for statistical analysis and mapping：1. describing the metering money in baseline characteristic
Material selects mean, standard deviation, median, quartile spacing.The number of cases and percentage of all kinds of generations of enumeration data are described.Between group
Compare, measurement data is using the side such as variance analysis, paired t-test, Kruskal-Wallis H inspections, Wilcoxon rank sum tests
Method；Enumeration data accurately examined using Fisher, Chi-square Test etc., and ranked data are examined using Kruskal-Wallis H.
3 results
3.1 are included in case
From on January 4th, 2013 until 30 days December in 2016, which screens altogether 246 patients, is randomly divided into 3
Group, every group 82.Fall off 4 cases altogether, wherein 2 are complex group, treatment group and each 1 of heart treasure pill group.Finally have 242 by
Examination person's qualification enters statistical analysis.Male 122 in 242 subjects, women 120, minimal ages 40 years old, max age
84 years old.Sinus bradycardia has 110, and sick sinus syndrome has 68, and atrial fibrillation has 64 with long pause.
3.2 Baseline Data
The data of subject's baseline are shown in Table 1.Wherein the average age for the treatment of group is 61.32 years old, the average year of heart treasure pill group
Age is 61.45 years old, and the average age of complex group is 60.89 years old.The crowd of hypertension occupies 43.21% in treatment group, heart treasure pill
Group occupies 45.68%, and complex group occupies 45.00% (p>0.05).Diabetic occupies 25.93% in treatment group, and the heart is precious
Occupy 24.69% in ball group, 23.75% (p is occupied in control group>0.05).Hyperlipidemia patient occupies in No. 2 groups of calming heart
20.99%, occupy 19.75% in heart treasure pill group, 18.75% (p is occupied in complex group>0.05).The height of three groups of patients in group,
Weight, systolic pressure, diastolic pressure, resting heart rate, drug combination, medical history are consistent, no difference of science of statistics (p>0.05).
1 subject's Baseline Data project of table
3.3 Syndrome Differentiation of Traditional Chinese Medicine features and elements of TCM syndromes
Syndrome Differentiation of Traditional Chinese Medicine belongs to based on void more, actual situation holds miscellaneous card under the arm.Wherein more than four one-tenth more than patient's Chinese medical discrimination category
Yang-energy virtual loss, remaining is followed successively by the cards types such as deficiency of both qi and yin, qi deficiency to blood stasis and the resistance of blood stasis phlegm.Three groups of each card type distributions are almost the same,
No difference of science of statistics (p>0.05), TCM Syndrome Type distribution situation is shown in Table 2.Nervous, syncope, shortness of breath, tired, chest uncomfortable in chest in view of palpitaition
Bitterly, six indexs of pulse condition have leading meaning on the tcm diagnosis of slow arrhythmia, it is thus determined that its Chinese medicine primary symptom is demonstrate,proved
Waiting element is：Palpitaition is nervous, syncope, shortness of breath, tired, feeling of oppression and pain in the chest, pulse condition, by light 3 points, in 6 points, weigh 9 and divide scoring, each primary symptom
Integral estimation standard is shown in Table 3.In view of spontaneous perspiration, night sweat, aversion to cold and cold limbs, six poor, complexion, tongue picture indexs are received in the mistake of the Retarder theory rhythm of the heart
Also there is important references value, it is thus determined that its Chinese medicine minor symptom elements of TCM syndromes is on normal tcm diagnosis：Spontaneous perspiration, night sweat, chilly
Limb is cold, receives poor, complexion, tongue picture, by light 1 point, in 2 points, weigh 3 scoring, each minor symptom integral estimation standard divided to be shown in Table 4.
2 slow arrhythmia TCM Syndrome Type distribution situation of table compares
| Group | Number of cases | Yang-energy virtual loss example (%) | Deficiency of both qi and yin example (%) | Qi deficiency to blood stasis example (%) | Blood stasis phlegm hinders example (%) |
| Treatment group | 81 | 36(44.44) | 18(22.22) | 14(17.28) | 13(16.05) |
| Heart treasure pill group | 81 | 35(43.21) | 18(22.22) | 14(17.28) | 14(17.28) |
| Complex group | 80 | 34(42.50) | 17(21.25) | 15(18.75) | 14(17.50) |
The 3 slow arrhythmia tcm syndrome element primary symptom table of integrals of table
The 4 slow arrhythmia tcm syndrome element primary symptom table of integrals of table
The effect of 3.4 pairs of ventricular rates
According to average ventricular rate curative effect determinate standard, effective 44 for the treatment of group, effective 25, invalid 12, total effective rate
It is 85.19%；Effective 34 of heart treasure pill group, effective 19, invalid 28, total effective rate 65.43%；Complex group effective 14
Example, effective 19, invalid 47, total effective rate 41.25%.Treatment group, heart treasure pill group total effective rate are apparently higher than complex group
(p ＜ 0.01), and treatment group's total effective rate is apparently higher than heart treasure pill group (p ＜ 0.01), and statistical result is shown in Table 5.Treatment group, the heart
The pretherapy and post-treatment 24 hours ventricular rates of treasure pill group compare, most slow heart rate, most fast heart rate and the significant difference of average ventricular rate
(p ＜ 0.01) prompts drug of the present invention and heart treasure pill that the average ventricular rate of slow arrhythmia patient, the most slow heart can be improved
Rate and most fast heart rate, and treatment group is better than heart treasure pill group (p ＜ 0.01), shows that curative effect of medication of the present invention is best.Complex group is controlled
It treats forward backward averaging ventricular rate and also slightly improves (p ＜ 0.05), but is little to most slow heart rate, most fast Heart rate influences, statistical result is shown in
Table 6.
5 treatment group of table is compared with the effect of other group treatment slow arrhythmias are averaged ventricular rate
| Group | Number of cases | Effective example (%) | Effective example (%) | Invalid example (%) | Total effective rate |
| Treatment group | 81 | 44(54.32) | 25(30.86) | 12(14.81) | 85.19%**▲▲ |
| Heart treasure pill group | 81 | 34(41.98) | 19(23.46) | 28(34.57) | 65.43%** |
| Complex group | 80 | 14(17.50) | 19(23.75) | 47(58.75) | 41.25% |
Note：* expressions are compared with complex group, p ＜ 0.01；▲▲It indicates compared with heart treasure pill, p ＜ 0.01.
6 treatment group of table is compared with the effect of other organize pretherapy and post-treatment ventricular rates
Note：△It indicates compared with before treatment, p ＜ 0.05,△△It indicates compared with before treatment, p ＜ 0.01.
The effect of 3.5 pairs of tcm syndromes
According to Chinese medicine syndrome integral curative effect determinate standard, clinical recovery 30 after treatment group's treatment, effective 29, effective 17
Example, invalid 5, total effective rate 93.83%；Clinical recovery 20 after the treatment of heart treasure pill group, effective 22, effective 18, nothing
Effect 21, total effective rate 74.07%；Clinical recovery 12 after complex group treatment, effective 14, effective 15, invalid 39,
Total effective rate is 51.25%.Treatment group, heart treasure pill group total effective rate are apparently higher than complex group (p ＜ 0.01), and treatment group is total
Effective percentage is apparently higher than heart treasure pill group, and two groups are compared p ＜ 0.01, and statistical result is shown in Table 7.Pretherapy and post-treatment Chinese medicine syndrome integral ratio
Compared with through statistical test, treatment group, the pretherapy and post-treatment Chinese medicine syndrome integral of heart treasure pill group have difference (the p ＜ of statistical significance
0.01), prompt drug of the present invention and heart treasure pill that can improve the tcm clinical practice syndrome of patient, statistical result is shown in Table 8.
7 treatment group of table is compared with the effect of other groups treat slow arrhythmia tcm syndromes
Note：* expressions are compared with complex group, p ＜ 0.01；▲▲Treatment group is indicated compared with heart treasure pill, p ＜ 0.01.
The variation of 8 pretherapy and post-treatment each group Chinese medicine syndrome integral of table is compared (x ± s)
Note：△It indicates compared with before treatment, p ＜ 0.05,△△It indicates compared with before treatment, p ＜ 0.01.
The effect of 3.6 pairs of each card types, is analyzed
The curative effect basis equalization in each card type for the treatment of group, in each card type group total effective rate 84.62% to 97.22% it
Between, illustrate that drug of the present invention can play preferable curative effect for each card type of slow arrhythmia, statistical result is shown in Table 9.And
It is the most notable with yang-energy deficiency curative effect in each card type of heart treasure pill group, secondly it is Qi deficiency blood stasis type, total effective rate is respectively
97.14% and 78.57%.Type of deficiency of both QI and YIN total effective rate is 33.33%, illustrates heart treasure pill to yang-energy deficiency, qi deficiency to blood stasis
Type therapeutic effect is preferable, and then curative effect religion is poor to type of deficiency of both QI and YIN, and statistical result is shown in Table 10.Then with qi deficiency to blood stasis in complex group
It is preferable with blood stasis phlegm retention curative effect, and it is poor to yang-energy virtual loss, type of deficiency of both QI and YIN curative effect, and statistical result is shown in Table 11.
The effect of each TCM Syndrome Type of 9 treatment group of table, compares
| TCM Syndrome Type | Number of cases | Example of fully recovering (%) | Effective example (%) | Effective example (%) | Invalid example (%) | Total effective rate |
| Yang-energy virtual loss | 36 | 17(47.22) | 15(41.67) | 3(8.33) | 1(2.78) | 97.22% |
| Deficiency of both qi and yin | 18 | 7(38.89) | 5(27.78) | 5(27.78) | 1(5.56) | 94.44% |
| Qi deficiency to blood stasis | 14 | 4(28.57) | 4(28.57) | 5(35.71) | 1(7.14) | 92.86% |
| Blood stasis phlegm hinders | 13 | 2(15.38) | 5(38.46) | 4(30.77) | 2(15.38) | 84.62% |
| It is total | 81 | 30(37.04) | 29(35.80) | 17(20.99) | 5(6.17) | 93.83% |
The effect of each TCM Syndrome Type of 10 heart treasure pill group of table, compares
Note：The * p ＜ 0.05 compared with yang-energy virtual loss, * * p ＜ 0.01；Compared with deficiency of both qi and yin△△P ＜ 0.01.
The effect of each TCM Syndrome Type of 11 complex group of table, compares
| TCM Syndrome Type | Number of cases | Example of fully recovering (%) | Effective example (%) | Effective example (%) | Invalid example (%) | Total effective rate |
| Yang-energy virtual loss | 34 | 2(5.88) | 2(5.88) | 3(8.82) | 27(79.41) | 20.59%△ |
| Deficiency of both qi and yin | 17 | 2(11.76) | 2(11.76) | 3(16.64) | 10(58.82) | 41.18%* |
| Qi deficiency to blood stasis | 15 | 3(20.00) | 5(33.33) | 6(40.00) | 1(6.67) | 93.33%**△ |
| Blood stasis phlegm hinders | 14 | 5(35.71) | 5(35.71) | 3(21.43) | 1(7.14) | 92.86%**△ |
| It is total | 80 | 12(17.50) | 14(17.50) | 15(23.75) | 39(48.75 | 51.25% |
Note：The * p ＜ 0.05 compared with yang-energy virtual loss, * * p ＜ 0.01；Compared with deficiency of both qi and yin△P ＜ 0.05,△△P ＜ 0.01.
The effect of 3.7 pairs of elements of TCM syndromes, is analyzed
By comparing the variation of pretherapy and post-treatment primary symptom elements of TCM syndromes, palpitaition is nervous, syncope, shortness of breath, tired, feeling of oppression and pain in the chest,
Six indexs of pulse condition, treatment group and heart treasure pill group have clear improvement (p ＜ 0.01 or p ＜ 0.05), and treatment group's elements of TCM syndromes
Improve and more write (p ＜ 0.01), complex group, which only has part elements of TCM syndromes, to be improved.Prompt illustrates drug and the heart treasure pill of the present invention to slow
The primary symptom elements of TCM syndromes of chronic arrhythmia cordis is significantly improved, and invention drug improvement result is more notable, and statistical result is shown in Table
12。
The pretherapy and post-treatment primary symptom elements of TCM syndromes variation of 12 each group of table is compared
Note：△It indicates compared with before treatment, p ＜ 0.05,△△It indicates compared with before treatment, p ＜ 0.01.
By to pretherapy and post-treatment minor symptom elements of TCM syndromes variation compare, treatment group to minor symptom spontaneous perspiration, night sweat, aversion to cold and cold limbs, receive
The syndromes whole element such as difference, complexion, tongue picture has clear improvement (p ＜ 0.01), and heart treasure pill group is then to spontaneous perspiration, aversion to cold and cold limbs, face
Color, tongue picture four indices have improvement, complex group then only to improve to complexion elements of TCM syndromes.Illustrate that drug of the present invention wants minor symptom syndrome
The improvement result of element is notable, and statistical result is shown in Table 13.
The pretherapy and post-treatment minor symptom elements of TCM syndromes variation of 13 each group of table is compared
Note：△It indicates compared with before treatment, p ＜ 0.05,△△It indicates compared with before treatment, p ＜ 0.01.
3.8 safety indexes are observed and evaluation
Over the course for the treatment of and during follow-up, three groups of subjects have no dizziness, Nausea and vomiting, agitation, expiratory dyspnea etc.
Serious adverse reaction, periodically to blood urine, just the number of lab index such as three big routine, hepatic and renal function, coagulation functions carries out observation point
Analysis, does not find apparent exception.In Adverse event monitoring, no adverse events occur.
4. discussing
4.1 Syndrome Differentiation of Traditional Chinese Medicine features and elements of TCM syndromes
Slow arrhythmia appears in weak or high year people or insufficiency of natural endowment, the innate deficiency of YANG in the body or year high gate of vitality mostly
Fire declines, and void, the disease feature of phlegm, the stasis of blood is presented easily from the moonization in perverse trend.Void is mainly the deficiency of yang, the deficiency of vital energy, and real is mainly blood stasis phlegm
Resistance.Our observation is that Syndrome Differentiation of Traditional Chinese Medicine belongs to based on void more, actual situation holds miscellaneous card under the arm.Wherein more than four one-tenth more than patient's Chinese medicine
Dialectical category yang-energy virtual loss, remaining is followed successively by the cards types such as deficiency of both qi and yin, qi deficiency to blood stasis and the resistance of blood stasis phlegm.Therefore the Retarder theory rhythm of the heart is lost
Normal treatment, should by temperature compensation heart kidney, rouse oneself yang-energy headed by be engaged in.In conjunction with previous clinical practice and long-term clinical observation, table
Bright slow arrhythmia is in the majority with the deficiency of yang, deficiency of vital energy person, often shows as based on void, the heart kidney yang gas virtual loss of simulataneous insufficiency and excessive, the heart
The stagnant obstructed syndrome of the arteries and veins stasis of blood, disease feature can be summarized as void, the stasis of blood, phlegm.The tcm clinical practice disease of comprehensive analysis slow arrhythmia
Card feature, in view of palpitaition, six nervous, syncope, shortness of breath, tired, feeling of oppression and pain in the chest, pulse condition indexs are in slow arrhythmia
There is leading meaning, it is thus determined that its Chinese medicine primary symptom elements of TCM syndromes is in doctor's diagnosis：Palpitaition is nervous, syncope, shortness of breath, tired, chest
Bored pectoralgia, pulse condition.In view of spontaneous perspiration, night sweat, aversion to cold and cold limbs, six poor, complexion, tongue picture indexs are received in slow arrhythmia
Also there is important references value, it is thus determined that its Chinese medicine minor symptom elements of TCM syndromes is in doctor's diagnosis：Spontaneous perspiration, aversion to cold and cold limbs, is received night sweat
Difference, complexion, tongue picture.
The influence of 4.2 pairs of slow arrhythmia hearts rate
Heart treasure pill is the Chinese patent drug of clinical treatment slow arrhythmia generally acknowledged in recent decades, by Guangdong heart treasured pharmacy
Company produce (Chinese medicines quasi-word Z44O21843), by datura flower, ginseng, Chinese cassia tree, monkshood, pilose antler, borneol, muscone, Radix Notoginseng,
Nine herbal medicine such as dried venom of toads forms, and has the effect of temperature compensation heart kidney, benefiting qi and supporting yang, blood circulation and channel invigorating.Be mainly used for treat heart-kidney yang deficiency,
Chronic cardiac insufficiency caused by heart arteries and veins stasis blocking, bradycardia, sick sinus syndrome and ischemic caused by sinus node dysfunction
Angina pectoris caused by heart disease and electrocardiogram ischemic lesions.Clinical test proves, compares according to average ventricular rate curative effect, and the heart is precious
Ball treatment slow arrhythmia truly has curative effect, total effective rate 65.43%, hence it is evident that total higher than by compound danshen dripping pills and Radix Notoginseng
The 41.25% of the complex group of glycosides piece and Inosine tablets composition, but heart treasure pill temperature compensation effect is had a surplus, supplementing qi and nourishing yin and work promoting blood circulation and removing blood stasis
With deficiency, thus it is clinically somewhat limited, also influence the performance of whole curative effect.Drug of the present invention is by seven taste Chinese medicine groups
At using Herba Epimedii, Chinese cassia tree temperature compensation heart kidney, rousing oneself yang-energy as monarch drug in a prescription；With Radix Astragali, Schisandra chinensis benefiting qi and nourishing yin nourishing heart, rhodiola root, Radix Notoginseng
It is promoting blood circulation and removing blood stasis to promote blood circulation as ministerial drug；It is to make medicine with dried orange peel regulating qi-flowing for eliminating phlegm, coordinating the drug actions of a prescription.All medicine phases 5, gather altogether temperature compensation heart kidney, QI invigorating support
The effect of the moon, blood circulation and channel invigorating.According to average ventricular rate curative effect determinate standard, drug total effective rate of the present invention is 85.19%, remote high
In 65.43% (p ＜ 0.01) of heart treasure pill.The flat of slow arrhythmia patient can be improved in invention drug and heart treasure pill simultaneously
Equal heart rate, most slow heart rate and most fast heart rate, and it is especially best with invention curative effect of medication.
The influence of 4.3 pairs of tcm syndromes and element
According to Chinese medicine syndrome integral curative effect determinate standard, treatment group's total effective rate is 93.83%, heart treasure pill group total effective rate
It is 74.07%, complex group total effective rate is 51.25%.Treatment group, heart treasure pill group curative effect are apparently higher than complex group (p ＜ 0.01),
And treatment group's curative effect is apparently higher than heart treasure pill group (p ＜ 0.01) again.And compared by pretherapy and post-treatment Chinese medicine syndrome integral, it carries
The tcm clinical practice syndrome of patient can be improved by showing invention medicine and heart treasure pill.In terms of heart treasure pill improves the tcm clinical practice syndrome of patient,
It is the most notable with yang-energy deficiency curative effect, it is secondly Qi deficiency blood stasis type, poor is type of deficiency of both QI and YIN, illustrates that heart treasure pill loses yang-energy
Deficiency, Qi deficiency blood stasis type therapeutic effect are preferable, and then curative effect religion is poor to type of deficiency of both QI and YIN.And curative effect is basic in each card type for the treatment of group
Equilibrium, total effective rate illustrates that invention medicine is each for slow arrhythmia between 84.62% to 97.22% in each card type group
Card type can play preferable curative effect, be suitable for the treatment of the slow arrhythmia of each TCM Syndrome Type.
By analyzing the effect of elements of TCM syndromes, in terms of primary symptom elements of TCM syndromes, invention medicine is nervous, dizzy to improving palpitaition
Faint, shortness of breath, tired, feeling of oppression and pain in the chest, pulse condition six indexs effect it is notable, heart treasure pill group also has improvement result, illustrates invention drug
The primary symptom elements of TCM syndromes of slow arrhythmia is significantly improved with heart treasure pill.In terms of minor symptom elements of TCM syndromes, hair
Bright drug has clear improvement to minor symptom spontaneous perspiration, night sweat, aversion to cold and cold limbs, the syndromes such as poor, complexion, tongue picture of receiving, and heart treasure pill is then to certainly
Sweat, aversion to cold and cold limbs, complexion, tongue picture four indices have improvement, and complex group then only improves complexion elements of TCM syndromes, and drug of the present invention
It is more notable to the minor symptom syndrome improvement result of slow arrhythmia.
5, conclusion
Drug of the present invention can effectively treat slow arrhythmia, improve the tcm syndrome of slow arrhythmia, press
According to generally acknowledged curative effect standard, with control group drug heart treasure pill and Radix Notoginseng total glucosides tablet, compound danshen dripping pills, Inosine tablets drug combination
The effect of compare, otherness have significant (P ＜ 0.01), illustrate drug therapy slow arrhythmia curative effect of the present invention
Significantly.In addition, during clinical observation, do not find that drug of the present invention has any bad toxicity, shows that this drug is one
Safe and effective preparation.
Specific implementation mode
Embodiment 1 (granule)
1, prescription：Herba Epimedii 2500g, Chinese cassia tree 1000g, Radix Astragali 2000g, Schisandra chinensis 1500g, rhodiola root 1000g, Radix Notoginseng
1000g, dried orange peel 1000g.
2, preparation method：
(1) Radix Notoginseng is taken, adds 8 times of 70% alcohol heat reflux of amount to extract 3 times, 1.5 hours every time, collects and merge alcohol extract, filter
It crosses, decompression filtrate recycling ethanol is simultaneously concentrated into the medicinal extract that relative density is 1.10 at 60 DEG C, spare；
(2) remaining bulk pharmaceutical chemicals outside Radix Notoginseng are removed, are added water to cook 3 times, are fried by intense fire after boiling for the first time 30 minutes, second
It fries by intense fire 1 hour, is fried by intense fire after boiling for the third time 1.5 hours, collecting decoction after boiling, filtered, filtrate decompression is concentrated into 80 DEG C
The medicinal extract that relative density is 1.25, it is spare；
(3) medicinal extract obtained by step (1) (2) is collectively disposed in baking oven, dry cream is baked at 75 DEG C, be ground into thin
Powder；
(4) it takes the fine powder obtained by step (3) that appropriate dextrin and starch is added to 1000g, adds water and particle is made, then
Dry, whole grain is distributed into 15g/ packets (including often dry powder drug about 7.8g).
Embodiment 2 (granule)
1, prescription：Herba Epimedii 2600g, Chinese cassia tree 900g, Radix Astragali 2200g, Schisandra chinensis 1400g, rhodiola root 1100g, Radix Notoginseng
900g, dried orange peel 900g.
2, preparation method：
Granule is made according to method described in embodiment 1.
Embodiment 3 (granule)
1, prescription：Herba Epimedii 2500g, Chinese cassia tree 900g, Radix Astragali 2200g, Schisandra chinensis 1700g, rhodiola root 900g, Radix Notoginseng
900g, dried orange peel 900g.
2, preparation method：
Granule is made according to method described in embodiment 1.
Embodiment 4 (granule)
1, prescription：Herba Epimedii 2800g, Chinese cassia tree 1100g, Radix Astragali 1800g, Schisandra chinensis 1400g, rhodiola root 900g, Radix Notoginseng
900g, dried orange peel 1100g.
2, preparation method：
Granule is made according to method described in embodiment 1.
Embodiment 5 (capsule)
The drug granule that embodiment 1 is prepared into is packed into gelatine capsule, capsule is made.
Embodiment 5 (tablet)
Tablet is made using conventional method tabletting in the drug granule that embodiment 1 is prepared into.
Claims (4)
1. a kind of drug for treating slow arrhythmia, the drug is by effective ingredient and medically acceptable excipient group
At wherein the effective ingredient is made of the bulk pharmaceutical chemicals of following weight percent：Herba Epimedii 23~28%, Chinese cassia tree 9~11%,
Radix Astragali 18~22%, Schisandra chinensis 14~17%, rhodiola root 9~11%, Radix Notoginseng 9~11%, dried orange peel 9~11%.
2. a kind of drug for treating slow arrhythmia according to claim 1, which is characterized in that it is described it is effective at
Part is made of the bulk pharmaceutical chemicals of following weight percent：Herba Epimedii 25%, Chinese cassia tree 10%, Radix Astragali 20%, Schisandra chinensis 15%, rhodiola root
10%, Radix Notoginseng 10%, dried orange peel 10%.
3. a kind of drug for treating slow arrhythmia according to claim 1 or 2, which is characterized in that the medicine
Object is prepared by following methods：
(1) Radix Notoginseng is taken, adds 8 times of 70% alcohol heat reflux of amount to extract 3 times, 1.5 hours every time, collects and merge alcohol extract, filter, filter
Liquid is recovered under reduced pressure ethyl alcohol and is concentrated into medicinal extract, spare；
(2) remaining bulk pharmaceutical chemicals outside Radix Notoginseng are removed, are added water to cook 3 times, fries by intense fire after boiling for the first time 30 minutes, boils for the second time
After fry by intense fire 1 hour, fried by intense fire after boiling for the third time 1.5 hours, collecting decoction, filter, filtrate decompression is concentrated into medicinal extract, standby
With；
(3) medicinal extract obtained by step (1) and (2) is collectively disposed in baking oven, bakes dry cream at 75 DEG C, is ground into fine powder；
(4) it takes the fine powder obtained by step (3) that suitable acceptable excipient of medicine is added, is made according to a conventional method common
Solid oral agent.
4. a kind of drug for treating slow arrhythmia according to claim 3, which is characterized in that the solid port
It is granule, capsule or tablet to take agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810852307.2A CN108578510A (en) | 2018-07-30 | 2018-07-30 | A kind of drug for treating slow arrhythmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810852307.2A CN108578510A (en) | 2018-07-30 | 2018-07-30 | A kind of drug for treating slow arrhythmia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108578510A true CN108578510A (en) | 2018-09-28 |
Family
ID=63618463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810852307.2A Pending CN108578510A (en) | 2018-07-30 | 2018-07-30 | A kind of drug for treating slow arrhythmia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108578510A (en) |
-
2018
- 2018-07-30 CN CN201810852307.2A patent/CN108578510A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102771791A (en) | Healthcare food and preparation method and application thereof | |
| CN110327427A (en) | It is a kind of to treat morning, the Chinese medicine composition of mid-term high blood pressure and preparation method | |
| CN109985209A (en) | A kind of Chinese medicine composition and its preparation method and application for treating advanced gastric carcinoma | |
| CN113827657A (en) | Traditional Chinese medicine composition preparation for treating epidemic cold (qi-yin deficiency syndrome) and application | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN108578510A (en) | A kind of drug for treating slow arrhythmia | |
| CN102988696A (en) | Traditional Chinese medicinal composition used for treating coronary heart disease angina pectoris, and its use | |
| CN106177759B (en) | A kind of compound Chinese medicinal preparation and its preparation process for treating coronary disease and angina pectoris | |
| CN113041300B (en) | Prescription for treating diabetes and its application | |
| CN105055967B (en) | A kind of complex health care product and preparation method with auxiliary hyperglycemic function | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN107837384A (en) | A kind of Chinese medicine composition for treating hand-foot-and-mouth disease | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN105287755B (en) | A kind of Chinese medicine composition treating sepsis cardiac dysfunction | |
| CN113599447A (en) | Traditional Chinese medicine composition for improving phlegm-dampness constitution and preparation method and application thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN113288991A (en) | Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof | |
| CN100479842C (en) | Medicine for treating arrhythmia and preparation method thereof | |
| CN105726943B (en) | A kind of drug and preparation method of propafenone on ventricular premature beats | |
| CN107029164B (en) | Pure traditional Chinese medicine composition for treating cognitive function reduction and pure traditional Chinese medicine preparation prepared from same | |
| CN110548099A (en) | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method thereof | |
| CN101053626B (en) | Traditional Chinese medicine for treating coronary heart disease and angina pectoris and its preparation method | |
| CN100361683C (en) | Chinese medicinal preparation for treating fatly liver and its preparation method | |
| CN110464814A (en) | A kind of external application Chinese medicine and preparation method thereof for treating taste intestinal disease | |
| CN108310075A (en) | A kind of stilbene Chinese herbaceous peony blood circulation promoting medicine that treating diabete peripheral herve pathology and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180928 |